- Home
- RAPT vs CHRS Comparison
RAPT vs CHRS Comparison
Compare RAPT & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAPT
- CHRS
- Stock Information
- Founded
- RAPT 2015
- CHRS 2010
- Country
- RAPT United States
- CHRS United States
- Employees
- RAPT N/A
- CHRS N/A
- Industry
- RAPT Biotechnology: Pharmaceutical Preparations
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RAPT Health Care
- CHRS Health Care
- Exchange
- RAPT Nasdaq
- CHRS Nasdaq
- Market Cap
- RAPT 122.9M
- CHRS 102.0M
- IPO Year
- RAPT 2019
- CHRS 2014
- Fundamental
- Price
- RAPT $11.74
- CHRS $1.05
- Analyst Decision
- RAPT Buy
- CHRS Buy
- Analyst Count
- RAPT 5
- CHRS 3
- Target Price
- RAPT $33.60
- CHRS $4.68
- AVG Volume (30 Days)
- RAPT 105.9K
- CHRS 1.5M
- Earning Date
- RAPT 08-07-2025
- CHRS 08-07-2025
- Dividend Yield
- RAPT N/A
- CHRS N/A
- EPS Growth
- RAPT N/A
- CHRS N/A
- EPS
- RAPT N/A
- CHRS 1.55
- Revenue
- RAPT N/A
- CHRS $272,209,000.00
- Revenue This Year
- RAPT N/A
- CHRS N/A
- Revenue Next Year
- RAPT N/A
- CHRS $142.61
- P/E Ratio
- RAPT N/A
- CHRS $2.05
- Revenue Growth
- RAPT N/A
- CHRS 52.33
- 52 Week Low
- RAPT $5.67
- CHRS $0.66
- 52 Week High
- RAPT $26.56
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- RAPT 58.44
- CHRS 62.88
- Support Level
- RAPT $10.20
- CHRS $0.81
- Resistance Level
- RAPT $13.50
- CHRS $0.95
- Average True Range (ATR)
- RAPT 1.01
- CHRS 0.07
- MACD
- RAPT -0.05
- CHRS 0.01
- Stochastic Oscillator
- RAPT 77.46
- CHRS 85.71
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.